High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation - PubMed (original) (raw)
Clinical Trial
. 2011 Sep 29;118(13):3504-11.
doi: 10.1182/blood-2011-01-329441. Epub 2011 Jun 28.
Nadezda Basara, Herrad Baurmann, Joachim Beck, Monika Brüggemann, Helmut Diedrich, Björn Güldenzoph, Gernot Hartung, Heinz-August Horst, Andreas Hüttmann, Guido Kobbe, Ralph Naumann, Richard Ratei, Albrecht Reichle, Hubert Serve, Matthias Stelljes, Andreas Viardot, Mohammed Wattad, Dieter Hoelzer
Affiliations
- PMID: 21715318
- DOI: 10.1182/blood-2011-01-329441
Free article
Clinical Trial
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
Nicola Gökbuget et al. Blood. 2011.
Free article
Abstract
Nelarabine, a purine analog with T-cell specific action, has been approved for relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (ALL/LBL). This is a report of a single-arm phase 2 study conducted in adults (18-81 years of age) with relapsed/refractory T-ALL/LBL. After 1 or 2 cycles, 45 of 126 evaluable patients (36%) achieved complete remission (CR), 12 partial remission (10%), and 66 (52%) were refractory. One treatment-related death was observed, and 2 patients were withdrawn before evaluation. A total of 80% of the CR patients were transferred to stem cell transplantation (SCT). Overall survival was 24% at 1 year (11% at 6 years). After subsequent SCT in CR, survival was 31% and relapse-free survival 37% at 3 years. Transplantation-related mortality was 11%. Neurologic toxicities of grade I-IV/grade III-IV were observed in 13%/4% of the cycles and 16%/7% of the patients. This largest study so far with nelarabine in adults showed impressive single-drug activity in relapsed T-ALL/T-LBL. The drug was well tolerated, even in heavily pretreated patients. A high proportion of CR patients were transferred to SCT with low mortality but a high relapse rate. Exploration of nelarabine in earlier stages of relapse (eg, increasing minimal residual disease), in front-line therapy, and in combination is warranted.
Similar articles
- FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH, Johnson JR, Justice R, Pazdur R. Cohen MH, et al. Oncologist. 2008 Jun;13(6):709-14. doi: 10.1634/theoncologist.2006-0017. Oncologist. 2008. PMID: 18586926 - Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Abaza Y, et al. Am J Hematol. 2018 Jan;93(1):91-99. doi: 10.1002/ajh.24947. Epub 2017 Nov 3. Am J Hematol. 2018. PMID: 29047158 - Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, Del Principe MI, Bonifacio M, Mosna F, Delia M, Minetto P, Gottardi M, Fracchiolla N, Mancini V, Forghieri F, Zappasodi P, Cerrano M, Vitale A, Audisio E, Trappolini S, Romani C, Defina M, Imbergamo S, Ciccone N, Santoro L, Cambò B, Iaccarino S, Dargenio M, Aprile L, Chiaretti S, Fanin R, Pizzolo G, Foà R. Candoni A, et al. Am J Hematol. 2020 Dec;95(12):1466-1472. doi: 10.1002/ajh.25957. Epub 2020 Aug 31. Am J Hematol. 2020. PMID: 32777149 Clinical Trial. - The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY, Bydanov OI, Popov AM, Olshanskaya YV, Boichenko EG, Aleynikova OV, Maschan MA, Shelikhova LN, Litvinov DV, Khachatryan LA, Ponomareva NI, Fechina LG, Novichkova GA, Pashanov ED, Karachunskiy AI. Dyakonova YY, et al. Ter Arkh. 2018 Aug 17;90(7):38-50. doi: 10.26442/terarkh201890738-50. Ter Arkh. 2018. PMID: 30701921 Review. - Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ. DeAngelo DJ. Hematol Oncol Clin North Am. 2009 Oct;23(5):1121-35, vii-viii. doi: 10.1016/j.hoc.2009.07.008. Hematol Oncol Clin North Am. 2009. PMID: 19825456 Review.
Cited by
- Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.
Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, Maziarz RT, Champlin RE, Hosing C, Kebriaei P. Brammer JE, et al. Bone Marrow Transplant. 2017 Jan;52(1):20-27. doi: 10.1038/bmt.2016.194. Epub 2016 Sep 12. Bone Marrow Transplant. 2017. PMID: 27618682 Free PMC article. Clinical Trial. - Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia.
Gao H, Lou S, Hong H, Ge Q, Zhao H. Gao H, et al. Biomed Res Int. 2020 Feb 14;2020:1520651. doi: 10.1155/2020/1520651. eCollection 2020. Biomed Res Int. 2020. PMID: 32149078 Free PMC article. - Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S, DeAngelo DJ, Luskin MR. Shimony S, et al. Blood Adv. 2024 Jan 9;8(1):23-36. doi: 10.1182/bloodadvances.2023010303. Blood Adv. 2024. PMID: 37389830 Free PMC article. Review. - Treatment of Older Patients with Acute Lymphoblastic Leukaemia.
Gökbuget N. Gökbuget N. Drugs Aging. 2018 Jan;35(1):11-26. doi: 10.1007/s40266-017-0503-5. Drugs Aging. 2018. PMID: 29256044 Review. - [Current treatment of acute lymphoblastic leukemia in adults].
Gökbuget N. Gökbuget N. Internist (Berl). 2015 Apr;56(4):344-53. doi: 10.1007/s00108-014-3595-6. Internist (Berl). 2015. PMID: 25776794 German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources